Ebola Outbreak in the DRC: Can Existing Vaccines Contain the Deadliest Epidemic in the Country’s History?

Health authorities are racing to contain the largest Ebola outbreak in the history of the Democratic Republic of the Congo (DRC). Caused by the rare Bundibugyo strain of the Ebola virus, the outbreak has been declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization. With more than 6,000 reported cases and 3,000 deaths, global health leaders now face a critical question: can existing Ebola vaccines help stop the spread?

A major new modeling study published in The Lancet Infectious Diseases, led by Stanford Medicine researchers, offers the most detailed answer yet — and it comes at a pivotal moment, as the WHO begins shipping doses of the licensed Ervebo vaccine to the DRC.

What Is Happening: The Ebola Outbreak in the DRC

Ebola is spreading rapidly through eastern DRC, an area already battered by armed conflict, mass displacement and severe cuts to international health funding. This is not the Zaire strain that caused past epidemics. The culprit is Bundibugyo virus, a rarer Ebola species with no approved vaccine or treatment specifically designed for it.

Key numbers as of early September 2026:

• More than 6,186 reported cases and 3,007 reported deaths
• Around one in two cases is fatal
• Cases have now been confirmed in Uganda and France, showing the outbreak can cross borders
• Health workers warn that only about one-third of cases and deaths may be detected, meaning true numbers could be far higher

The outbreak is the second deadliest Ebola epidemic ever recorded, behind only the 2014 West Africa outbreak, and the deadliest in DRC history.

Why This Ebola Outbreak Is Different

Several factors make this epidemic unusually dangerous. First, responders are struggling to keep pace: roughly two-thirds of new cases appear in people who were not on any known contact list, which means the virus is spreading faster than contact tracers can follow it. Second, the region’s health system is overwhelmed by conflict, food insecurity and displacement. Third, there is no licensed vaccine or treatment matched to the Bundibugyo strain — the outbreak is unfolding before specific countermeasures can be deployed at scale.

Can the Existing Ebola Vaccine (Ervebo) Help?

Ervebo is the only licensed Ebola vaccine, but it was designed for the Zaire strain. Emerging data suggest it offers partial protection against Bundibugyo — researchers estimate roughly 45 percent effectiveness. In August 2026, the WHO began sending about 70,000 Ervebo doses to the DRC, a decision informed in part by the new Stanford-led analysis.

New Research: What the Lancet Modeling Study Found

The Stanford Medicine team, led by infectious disease professor Jason Andrews, modeled different ways a partially effective vaccine could be used. The findings are striking:

• Ring vaccination, the standard strategy of immunizing close contacts of confirmed cases, offered only limited benefit here, because so many new cases are not linked to known contacts
• Community-wide vaccination would be substantially more effective at reducing transmission and deaths
• However, community-wide campaigns would require millions of doses and robust delivery infrastructure that are not currently available
• Case finding and isolation were the single most important interventions, driving the largest reductions in mortality on their own
• Even with a highly effective vaccine, surveillance, isolation and contact tracing remain the foundation of outbreak control

The researchers shared their findings with the WHO analytics working group advising on vaccine use in the response.

New Bundibugyo-Specific Vaccines Are Coming

In a separate development, Moderna began the first human trial of a Bundibugyo-specific Ebola vaccine in August 2026. While promising, such a vaccine is still in early testing and will not be available in time to influence the current outbreak. Experts argue the episode underscores the need to invest in vaccine platforms now, so that emerging pathogens can be met with ready countermeasures when the next spillover occurs.

Public Health Response and Global Preparedness

The researchers stress that the DRC response is not a case of doing better with existing resources — the country needs more resources, period. Prior Ebola outbreaks have repeatedly crossed borders, and the appearance of cases in Uganda and France shows the global community cannot treat this as a regional problem.

For international travelers, health agencies advise staying informed through official WHO and national health updates, avoiding non-essential travel to active outbreak zones, and following screening and guidance at airports in affected regions. Ebola spreads through direct contact with bodily fluids of infected people, not through casual airborne transmission, which is why rigorous isolation of cases is so powerful.

Frequently Asked Questions

What is the Bundibugyo virus?

Bundibugyo virus is one of several species of Ebola virus. It causes Ebola disease with symptoms similar to other strains, including fever, severe headache, vomiting, diarrhea and bleeding. It is fatal in about half of cases and currently has no strain-specific licensed vaccine or treatment.

How does Ebola spread?

Ebola spreads through direct contact with the blood or bodily fluids of a person who is sick with or has died from the disease. It can also spread through contact with contaminated objects and surfaces. People are not contagious until they develop symptoms.

Is the current Ebola vaccine effective against this outbreak?

The licensed Ervebo vaccine targets the Zaire strain. Against Bundibugyo virus it is thought to provide partial protection, estimated at around 45 percent. New modeling shows it can still reduce transmission and save lives if deployed broadly and rapidly, alongside case finding and isolation.

Should travelers be worried about Ebola?

Risk to the general public outside affected areas remains low. Travelers should follow official guidance, avoid outbreak zones, practice good hand hygiene and seek medical care immediately if they develop fever after returning from an affected region.

What can be done to prevent future outbreaks?

Experts call for stronger investment in surveillance, public health systems in outbreak-prone regions and vaccine platforms that can be adapted quickly when new pathogens emerge. Most new infections arise from animal spillover events, which are expected to continue.

This article is based on reporting from the WHO, Stanford Medicine and peer-reviewed research in The Lancet Infectious Diseases, and is intended for information purposes only. It is not medical advice.